Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus pemetrexed and carboplatin in EGFR-mutant, T790M-negative NSCLC after EGFR-TKI failure
CTR20180275Phase 2Active
- Sponsor
- Junshi Biosciences
- Start
- Mar 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in non-small cell lung cancer (NSCLC), sponsored by Junshi Biosciences. Started Mar 2018; status: active.
02
Drugs
toripalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20180275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180275.